(NYSE: OGN) Organon & Co's forecast annual revenue growth rate of 1.2% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.95%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.5%.
Organon & Co's revenue in 2026 is $6,127,000,000.On average, 9 Wall Street analysts forecast OGN's revenue for 2026 to be $1,629,228,922,332, with the lowest OGN revenue forecast at $1,545,193,903,772, and the highest OGN revenue forecast at $1,710,900,455,995. On average, 9 Wall Street analysts forecast OGN's revenue for 2027 to be $1,653,388,990,168, with the lowest OGN revenue forecast at $1,541,517,371,710, and the highest OGN revenue forecast at $1,775,764,985,946.
In 2028, OGN is forecast to generate $1,664,943,805,220 in revenue, with the lowest revenue forecast at $1,534,952,135,885 and the highest revenue forecast at $1,796,773,740,586.